SBIR/STTR Research Award
DEVELOPMENT OF ANTI-CANCER AGENTS.
Award amount
$198,224Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VM DISCOVERY, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PHS2010-1
- Topic code
- NCI
Research abstract
The overall objective of this proposal is to preclinically develop VMD-1201 or a lead analog compound of a preferentially peripheral-acting PKC epsilon inhibitor as an oral targeted anticancer drug for treatment of human head and neck cancer with much reduced side effects. The long term goal of this developmental project is to develop this mechanism-based PKC epsilon specific inhibitor, through preclinical and human clinical trials, as an effective oral drug for advanced human head and neck cancer.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis